Alector, Inc.

Equities

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.25 ^USD	+9.15%		+3.14%	-34.21%

Apr. 17	Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI
Apr. 17	Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI

Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 27, 2024 at 04:19 pm EST

Alector, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 130.39 million compared to USD 133.31 million a year ago. Basic loss per share from continuing operations was USD 1.56 compared to USD 1.62 a year ago.

Latest news about Alector, Inc.

Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	Apr. 16	CI
Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	Apr. 16	CI
Certain Common Stock of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	Apr. 16	CI
Alector, Inc. Announces Board Changes	Mar. 21	CI
Transcript : Alector, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	Mar. 13
Transcript : Alector, Inc., 2023 Earnings Call, Feb 27, 2024	Feb. 27
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	Feb. 27	CI
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	Feb. 08	CI
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	Feb. 07	MT
GSK: breakthrough therapy status in dementia	Feb. 07	CF
Alector, GSK Get FDA Breakthrough Designation for Latozinemab	Feb. 07	DJ
Alector, Inc. Announces the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Latozinemab	Feb. 07	CI
Alector Closes $75 Million Public Stock Offering	Jan. 19	MT
Alector Tumbles After Pricing $75 Million Stock Offering	Jan. 17	MT
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday	Jan. 17	MT
Alector Plans Common Stock Offering; Shares Fall After-Hours	Jan. 16	MT
North American Morning Briefing : Volatility -2-	Dec. 15	DJ
Alector Shares Rise After Stifel Upgrade	Dec. 14	MT
Stifel Upgrades Alector to Buy From Hold, Adjusts Price Target to $15 From $8	Dec. 14	MT
Transcript : Alector, Inc. - Special Call	Dec. 13
Deutsche Bank Initiates Coverage on Alector With Buy Rating, $12 Price Target	Dec. 12	MT
Transcript : Alector, Inc. - Special Call	Dec. 07
Alector Insider Sold Shares Worth $132,500, According to a Recent SEC Filing	Dec. 07	MT

Chart Alector, Inc.

Duration

Period

More charts

Company Profile

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimerâs disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alector, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.25 USD

Average target price

16.22 USD

Spread / Average Target

+208.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALECTOR, INC.	-34.21%	506M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs